DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR PRAZOSIN HYDROCHLORIDE
505(b)(2) Clinical Trials for Prazosin Hydrochloride
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00487032 ↗ | Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation | Completed | Brian J Lipworth | Phase 4 | 2008-05-01 | The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Prazosin Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | N/A | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. |
| NCT00108420 ↗ | Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance | Completed | VA Office of Research and Development | Phase 4 | 2003-10-01 | The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD. |
| NCT00148837 ↗ | Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis | Unknown status | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 | 2004-09-01 | Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis. |
| NCT00161473 ↗ | Alzheimer's in Long-Term Care--Treatment for Agitation | Completed | National Institute on Aging (NIA) | N/A | 2001-01-01 | The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life. |
| NCT00161473 ↗ | Alzheimer's in Long-Term Care--Treatment for Agitation | Completed | University of Washington | N/A | 2001-01-01 | The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life. |
| NCT00167687 ↗ | Prazosin Alcohol Dependence IVR Study | Completed | VA Office of Research and Development | Phase 4 | 2005-09-01 | This double-blind placebo controlled pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduced alcohol consumption and alcohol craving in alcohol dependent individuals without Post Traumatic Stress Disorder (PTSD). The intervention period is six weeks. |
| NCT00167687 ↗ | Prazosin Alcohol Dependence IVR Study | Completed | University of Washington | Phase 4 | 2005-09-01 | This double-blind placebo controlled pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduced alcohol consumption and alcohol craving in alcohol dependent individuals without Post Traumatic Stress Disorder (PTSD). The intervention period is six weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Prazosin Hydrochloride
Condition Name
Clinical Trial Locations for Prazosin Hydrochloride
Trials by Country
Clinical Trial Progress for Prazosin Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Prazosin Hydrochloride
Sponsor Name
